Federal Register / Vol. 74, No. 161 / Friday, August 21, 2009 / Proposed Rules 42217 

(e) Reporting information for all 

manufacturers (Form 3500A, Block G). 

You must submit the following: 

(1) Your reporting office’s contact 

name and address and device 

manufacturing site; 

(2) The contact’s telephone number; 

(3) Your report sources; 

(4) Date received by you (month, day, 

year); 

(5) PMA/510k Number and whether 

or not the product is a combination 

product; 

(6) Type of report being submitted 

(e.g., 5–day, initial, followup); and 

(7) Your report number. 

* * * * * 

18. Revise the introductory text of 

§ 803.53 to read as follows: 

§ 803.53 If I am a manufacturer, in which 

circumstances must I submit a 5-day 

report? 

You must submit a 5-day report to us 

with the information required by 

§ 803.52 in accordance with the 

requirements of § 803.12(a) no later than 

5 work days after the day that you 

become aware that: 

* * * * * 

19. Amend § 803.56 by revising the 

introductory text and paragraphs (a) and 

(c) to read as follows: 

§ 803.56 If I am a manufacturer, in what 

circumstances must I submit a 

supplemental or followup report and what 

are the requirements for such reports? 

If you are a manufacturer, when you 

obtain information required under this 

part that you did not provide because it 

was not known or was not available 

when you submitted the initial report, 

you must submit the supplemental 

information to us within 30 calendar 

days of the day that you receive this 

information. You must submit the 

supplemental or followup report in 

accordance with the requirements of 

§ 803.12(a). On a supplemental or 

followup report, you must: 

(a) Indicate that the report being 

submitted is a supplemental or followup 

report; 

* * * * * 

(c) Include only the new, changed, or 

corrected information. 

Dated: August 11, 2009. 

Jeffrey Shuren, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E9–19683 Filed 8–20–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

21 CFR Part 1308 

[Docket No. DEA–331] 

Schedules of Controlled Substances: 

Placement of 5-Methoxy-N,NDimethyltryptamine Into Schedule I of 

the Controlled Substances Act 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice. 

ACTION: Notice of Proposed Rulemaking. 

SUMMARY: The Deputy Administrator of 

the Drug Enforcement Administration 

(DEA) is issuing this notice of proposed 

rulemaking to place the substance 5- 

methoxy-N,N-dimethyltryptamine (5- 

MeO-DMT) and its salts into schedule I 

of the Controlled Substances Act (CSA). 

This proposed action is based on a 

recommendation from the Acting 

Assistant Secretary for Health of the 

Department of Health and Human 

Services (DHHS) and on an evaluation 

of the relevant data by DEA. If finalized 

as proposed, this action would impose 

the criminal sanctions and regulatory 

controls of schedule I substances under 

the CSA on the manufacture, 

distribution, dispensing, importation, 

exportation, and possession of 5-MeODMT. 

DATES: Written comments must be 

postmarked, and electronic comments 

must be sent, on or before September 21, 

2009. Commenters should be aware that 

the electronic Federal Docket 

Management System will not accept 

comments after midnight Eastern time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–331’’ on all written and 

electronic correspondence. Written 

comments being sent via regular or 

express mail should be sent to the Drug 

Enforcement Administration, Attention: 

DEA Federal Register Representative/ 

ODL, 8701 Morrissette Drive, 

Springfield, VA 22152. Comments may 

be sent to DEA by sending an electronic 

message to 

dea.diversion.policy@usdoj.gov. 

Comments may also be sent 

electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at the 

http://www.regulations.gov Web site. 

DEA will accept electronic comments 

containing Microsoft Word, 

WordPerfect, Adobe PDF, or Excel files 

only. DEA will not accept any file 

format other than those specifically 

listed here. 

Please note that DEA is requesting 

that electronic comments be submitted 

before midnight Eastern time on the day 

the comment period closes because 

http://www.regulations.gov terminates 

the public’s ability to submit comments 

at midnight Eastern time on the day the 

comment period closes. Commenters in 

time zones other than Eastern time may 

want to consider this so that their 

electronic comments are received. All 

comments sent via regular or express 

mail will be considered timely if 

postmarked on the day the comment 

period closes. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D., Chief, 

Drug and Chemical Evaluation Section, 

Office of Diversion Control, Drug 

Enforcement Administration, 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: (202) 307–7183. 

SUPPLEMENTARY INFORMATION: 

Comments and Requests for Hearing 

In accordance with the provisions of 

the CSA (21 U.S.C. 811(a)), this action 

is a formal rulemaking ‘‘on the record 

after opportunity for a hearing.’’ Such 

proceedings are conducted pursuant to 

the provisions of the Administrative 

Procedure Act (5 U.S.C. 556 and 557). 

All persons are invited to submit their 

comments or objections with regard to 

this proposal. Requests for a hearing 

may be submitted by interested persons 

and must conform to the requirements 

of 21 CFR 1308.44 and 1316.47. The 

request should state, with particularity, 

the issues concerning which the person 

desires to be heard and the requestor’s 

interest in the proceeding. Only 

interested persons, defined in the 

regulations as those ‘‘adversely affected 

or aggrieved by any rule or proposed 

rule issuable pursuant to section 201 of 

the Act (21 U.S.C. 811),’’ may request a 

hearing. 

21 CFR 1308.42. Please note that DEA 

may grant a hearing only ‘‘for the 

purpose of receiving factual evidence 

and expert opinion regarding the issues 

involved in the issuance, amendment or 

repeal of a rule issuable’’ pursuant to 21 

U.S.C. 811(a). All correspondence 

regarding this matter should be 

submitted to the DEA using the address 

information provided above. 

Posting of Public Comments 

Please note that all comments 

received are considered part of the 

public record and made available for 

public inspection online at http:// 

www.regulations.gov and in the Drug 


CPrice-Sewell on DSKGBLS3C1PROD with PROPOSALS
42218 Federal Register / Vol. 74, No. 161 / Friday, August 21, 2009 / Proposed Rules 

Enforcement Administration’s public 

docket. Such information includes 

personal identifying information (such 

as your name, address, etc.) voluntarily 

submitted by the commenter. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want posted online or made 

available in the public docket in the first 

paragraph of your comment and identify 

what information you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted and the comment, in 

redacted form, will be posted online and 

placed in the Drug Enforcement 

Administration’s public docket file. 

Please note that the Freedom of 

Information Act applies to all comments 

received. If you wish to inspect the 

agency’s public docket file in person by 

appointment, please see the FOR

FURTHER INFORMATION CONTACT

paragraph. 

Background 

Explanation of 5-methoxy-N,Ndimethyltryptamine 

5-MeO-DMT is related to the schedule 

I hallucinogen, N,N-dimethyltryptamine 

(DMT), in its chemical structure and 

pharmacological properties. 5-MeODMT also shares pharmacological 

similarities with several other schedule 

I hallucinogens such as 2,5-dimethoxy4-methylamphetamine (DOM), lysergic 

acid diethylamide (LSD) and mescaline. 

In animal drug discrimination studies, 

DOM, LSD, mescaline, DMT, and alphamethyltryptamine (AMT) fully 

substitute for the discriminative 

stimulus cue of 5-MeO-DMT. In in vitro 

receptor binding studies, 5-MeO-DMT, 

similar to DMT and other schedule I 

hallucinogens, binds to central 

serotonin 2 (5-HT2) receptors. 

Studies show that the potencies of 

hallucinogens in humans correlate with 

their drug affinities for the 5-HT2

receptor and discriminative stimulus 

potencies. Accordingly, 5-MeO-DMT 

produces psychoactive effects in 

humans following inhalation (∼6–20 

mg), intravenous injection (∼0.7–3.1 

mg), sublingual (∼10 mg), intranasal 

insufflation (∼10 mg) and oral (∼30 mg) 

(if encapsulated or taken with a 

monoamine oxidase inhibitor) routes of 

administration. Anecdotal reports from 

humans who have used 5-MeO-DMT 

describe hallucinogenic effects similar 

to those produced by DMT. 5-MeODMT, however, is reported to be 4 to 5- 

fold more potent than DMT when 

administered by inhalation, sublingual 

or oral (if encapsulated) routes of 

administration. 

Control of 5-methoxy-N,Ndimethyltryptamine 

Evidence of the abuse of 5-MeO-DMT 

was first reported in 1999 by federal law 

enforcement personnel. According to 

the System to Retrieve Information on 

Drug Evidence (STRIDE), a federal 

database for seized drug exhibits 

analyzed by DEA laboratories, from 

January 1999 to December 2008, law 

enforcement seized 33 drug exhibits and 

filed 23 cases pertaining to the 

trafficking, distribution and abuse of 5- 

MeO-DMT. The seized drug exhibits 

comprised 89 grams of powder and 10 

milliliters of liquid containing 5-MeODMT. Since 2004, National Forensic 

Laboratory Information System (NFLIS), 

a database for drug cases analyzed by 

federal, state and local forensic 

laboratories, registered 23 state and 

local cases involving 27 analyzed items 

containing 5-MeO-DMT. 

There is evidence of clandestine 

laboratory operations to synthesize 5- 

MeO-DMT. 5-MeO-DMT has been 

encountered in powder, capsule, and 

liquid forms. 5-MeO-DMT is typically 

abused either by smoking or insufflating 

the powder. Investigations by federal 

law enforcement indicate that 

individuals, especially youths and 

young adults, are purchasing 5-MeODMT from Internet-based chemical 

suppliers. In addition, there are several 

instances where 5-MeO-DMT was sold 

as a counterfeit of MDMA. 

The risks to the public health 

associated with the abuse of 5-MeODMT are similar to the risks associated 

with those of schedule I hallucinogens. 

5-MeO-DMT can pose serious health 

risks to the user and general public 

through its ability to induce 

hallucinogenic effects and other sensory 

distortions and impaired judgment. Selfreports that are posted on Internet Web 

sites describe the abuse of this 

substance in combination with other 

controlled drugs such as DMT, N,Ndiethyltryptamine (DET), LSD, 

marijuana, ecstasy, or mushrooms 

(contains psilocybin and psilocin). This 

practice of drug abuse involving 

combinations can pose additional health 

risks to the users and the general public. 

These data show that the continued 

trafficking and abuse of 5-MeO-DMT 

pose hazards to the public health and 

safety. Indeed, there have been reports 

of emergency room admissions and 

death associated with the abuse of 5- 

MeO-DMT. 

There are no FDA-approved drug 

products. 5-MeO-DMT has never been 

approved by the FDA for marketing as 

a human drug product in the United 

States and there are no recognized 

therapeutic uses of 5-MeO-DMT in the 

United States. 

References to the above studies and 

data may be found in the Health and 

Human Services scheduling 

recommendation and DEA’s 

independent analysis, both of which are 

available on the electronic docket 

associated with this rulemaking. 

Placement of 5-MeO-DMT Into 

Schedule I 

In accordance with 21 U.S.C. 811(b) of 

the CSA, DEA has gathered and 

reviewed the available information 

regarding the pharmacology, chemistry, 

trafficking, actual abuse, pattern of 

abuse, and the relative potential for 

abuse of 5-MeO-DMT. On February 21, 

2007, the Deputy Administrator of the 

DEA submitted these data to the Acting 

Assistant Secretary for Health, 

Department of Health and Human 

Services. In accordance with 21 U.S.C. 

811(b), the Deputy Administrator also 

requested a scientific and medical 

evaluation and a scheduling 

recommendation for 5-MeO-DMT from 

the Acting Assistant Secretary for 

Health. On December 18, 2008, the 

Principal Deputy Assistant Secretary for 

Health, Department of Health and 

Human Services (DHHS), sent the 

Deputy Administrator of the DEA a 

scientific and medical evaluation and a 

letter recommending that 5-MeO-DMT 

and its salts be placed into schedule I 

of the CSA. Enclosed with the letter was 

a document prepared by FDA entitled, 

‘‘Basis for the Recommendation to 

Control 5-Methoxy-Dimethyltryptamine 

(5-MeO-DMT) in Schedule I of the 

Controlled Substances Act.’’ The 

document contained a review of the 

factors which the CSA requires the 


CPrice-Sewell on DSKGBLS3C1PROD with PROPOSALS
Federal Register / Vol. 74, No. 161 / Friday, August 21, 2009 / Proposed Rules 42219 

Secretary to consider (21 U.S.C. 811(b)). 

The factors considered by the Assistant 

Secretary of Health and DEA with 

respect to 5-MeO-DMT were: 

(1) Actual or relative potential for 

abuse; 

(2) Scientific evidence of its 

pharmacological effects, if known; 

(3) The state of current scientific 

knowledge regarding the drug; 

(4) History and current pattern of 

abuse; 

(5) The scope, duration, and 

significance of abuse; 

(6) What, if any, risk there is to the 

public health; 

(7) Psychic or physiological 

dependence liability; and 

(8) Whether the substance is an 

immediate precursor of a substance 

already controlled under the CSA. 

Based on the recommendation of the 

Assistant Secretary for Health, received 

in accordance with section 201(b) of the 

Act (21 U.S.C. 811(b)), and the 

independent review of the available 

data by DEA, the Deputy Administrator 

finds that sufficient data exist to support 

the placement of 5-MeO-DMT into 

schedule I of the CSA pursuant to 21 

U.S.C. 811(a). The specific findings 

required pursuant to 21 U.S.C. 811 and 

812 for 5-MeO-DMT to be placed into 

schedule I are as follows: 

(1) 5-MeO-DMT has a high potential 

for abuse. 

(2)5-MeO-DMT has no currently 

accepted medical use in treatment in the 

United States. 

(3) There is a lack of accepted safety 

for use of 5-MeO-DMT under medical 

supervision. 

Regulatory Requirements 

If this rule is finalized as proposed, 5- 

methoxy-N,N-dimethyltryptamine 

would be subject to regulatory controls 

and administrative, civil and criminal 

sanctions applicable to the manufacture, 

distribution, dispensing, importation 

and exportation of a schedule I 

controlled substance, including the 

following: 

Registration. Any person who 

manufactures, distributes, dispenses, 

imports or exports 5-methoxy-N,Ndimethyltryptamine or who engages in 

research or conducts instructional 

activities with respect to 5-methoxyN,N-dimethyltryptamine, or who 

proposes to engage in such activities, 

would be required to submit an 

application for schedule I registration in 

accordance with part 1301 of Title 21 of 

the Code of Federal Regulations. 

Security. 5-methoxy-N,Ndimethyltryptamine would be subject to 

schedule I security requirements and 

must be manufactured, distributed and 

stored in accordance with §§ 1301.71; 

1301.72(a), (c), and (d); 1301.73; 

1301.74; 1301.75(a) and (c); and 1301.76 

of Title 21 of the Code of Federal 

Regulations. 

Labeling and Packaging. All labels 

and labeling for commercial containers 

of 5-methoxy-N,N-dimethyltryptamine 

which are distributed on or after the 

effective date of a Final Rule finalizing 

this regulation would be required to 

comply with requirements of §§ 1302.03 

through 1302.07 of Title 21 of the Code 

of Federal Regulations. 

Quotas. Quotas for 5-methoxy-N,Ndimethyltryptamine would be 

established pursuant to the 

requirements of part 1303 of Title 21 of 

the Code of Federal Regulations. 

Inventory. Every registrant required to 

keep records and who possesses any 

quantity of 5-methoxy-N,Ndimethyltryptamine upon the effective 

date of any Final Rule finalizing these 

regulations would be required to keep 

an inventory of all stocks of the 

substance on hand pursuant to 

§§ 1304.03, 1304.04 and 1304.11 of Title 

21 of the Code of Federal Regulations. 

Every registrant who desires registration 

in schedule I to handle 5-methoxy-N,Ndimethyltryptamine would be required 

to conduct an inventory of all stocks of 

the substance. 

Records. All registrants who handle 5- 

methoxy-N,N-dimethyltryptamine 

would be required to keep records 

pursuant to §§ 1304.03, 1304.04 

1304.21, 1304.22, and 1304.23 of Title 

21 of the Code of Federal Regulations. 

Reports. All registrants required to 

submit reports in accordance with 

§ 1304.33 of Title 21 of the Code of 

Federal Regulations would be required 

to do so regarding 5-methoxy-N,Ndimethyltryptamine. 

Order Forms. All registrants involved 

in the distribution of 5-methoxy-N,Ndimethyltryptamine would be required 

to comply with the order form 

requirements of part 1305 of Title 21 of 

the Code of Federal Regulations. 

Importation and Exportation. All 

importation and exportation of 5- 

methoxy-N,N-dimethyltryptamine 

would be required to be in compliance 

with part 1312 of Title 21 of the Code 

of Federal Regulations. 

Criminal Liability. Any activity with 

5-methoxy-N,N-dimethyltryptamine not 

authorized by, or in violation of, the 

Controlled Substances Act or the 

Controlled Substances Import and 

Export Act occurring on or after the 

effective date of any Final Rule 

finalizing these regulations would be 

unlawful. 

Regulatory Certifications 

Executive Order 12866 

In accordance with the provisions of 

the CSA (21 U.S.C. 811(a)), this action 

is a formal rulemaking ‘‘on the record 

after opportunity for a hearing.’’ Such 

proceedings are conducted pursuant to 

the provisions of 5 U.S.C. 556 and 557 

and, as such, are exempt from review by 

the Office of Management and Budget 

pursuant to Executive Order 12866, 

section 3(d)(1). 

Regulatory Flexibility Act 

The Deputy Administrator, in 

accordance with the Regulatory 

Flexibility Act (5 U.S.C. 601–612), has 

reviewed this proposed rule and by 

approving it certifies that it will not 

have a significant economic impact on 

a substantial number of small entities. 

This proposed rule, if finalized, would 

place 5-methoxy-N,Ndimethyltryptamine into schedule I of 

the Controlled Substances Act. 

Executive Order 12988 

This regulation meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

Executive Order 13132 

This rulemaking does not preempt or 

modify any provision of State law; nor 

does it impose enforcement 

responsibilities on any State; nor does it 

diminish the power of any State to 

enforce its own laws. Accordingly, this 

rulemaking does not have federalism 

implications warranting the application 

of Executive Order 13132. 

Unfunded Mandates Reform Act of 1995 

This rule will not result in the 

expenditure by State, local and tribal 

governments, in the aggregate, or by the 

private sector, of $120,000,000 or more 

(adjusted for inflation) in any one year, 

and will not significantly or uniquely 

affect small governments. Therefore, no 

actions were deemed necessary under 

provisions of the Unfunded Mandates 

Reform Act of 1995. 

Congressional Review Act 

This rule is not a major rule as 

defined by § 804 of the Small Business 

Regulatory Enforcement Fairness Act of 

1996 (Congressional Review Act). This 

rule will not result in an annual effect 

on the economy of $100,000,000 or 

more; a major increase in costs or prices: 

or significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreign 


CPrice-Sewell on DSKGBLS3C1PROD with PROPOSALS
42220 Federal Register / Vol. 74, No. 161 / Friday, August 21, 2009 / Proposed Rules 

based companies in domestic and 

export markets. 

List of Subjects in 21 CFR Part 1308 

Administrative practice and 

procedure, Drug traffic control, 

Narcotics, Prescription drugs. 

Under the authority vested in the 

Attorney General by section 201(a) of 

the CSA (21 U.S.C. 811(a)), and 

delegated to the Administrator of DEA 

by Department of Justice regulations (28 

CFR 0.100), and redelegated to the 

Deputy Administrator pursuant to 28 

CFR 0.104, the Deputy Administrator 

hereby proposes that 21 CFR part 1308 

be amended as follows: 

PART 1308—SCHEDULES OF 

CONTROLLED SUBSTANCES 

1. The authority citation for part 1308 

continues to read as follows: 

Authority: 21 U.S.C. 811, 812, 871(b) 

unless otherwise noted. 

2. Section 1308.11 is amended by: 

A. Redesignating existing paragraphs 

(d)(15) through (d)(34) as paragraphs 

(d)(16) through (d)(35). 

B. Adding a new paragraph (d)(15). 

§ 1308.11 Schedule I. 

* * * * * 

(d) * * * 

(15) 5-methoxy-N,Ndimethyltryptamine, its isomers, salts 

and salts of isomers—7431. 

Some trade or other names: 5- 

methoxy-3-[2- 

(dimethylamino)ethyl]indole; 5-MeODMT. 

* * * * * 

Dated: August 12, 2009. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E9–20204 Filed 8–20–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

33 CFR Part 165 

[Docket No. USCG–2009–0720] 

RIN 1625–AA00 

Safety Zone; Ocean City Beachfront 

Air Show, Ocean City, NJ 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of proposed rulemaking. 

SUMMARY: The Coast Guard proposes to 

establish a temporary safety zone for the 

Ocean City Beachfront Air Show, an 

aerial demonstration to be held over the 

waters of the Atlantic Ocean adjacent to 

Ocean City, New Jersey. This Safety 

Zone is necessary to provide for the 

safety of life on navigable waters during 

the event. This proposed action would 

temporarily restrict vessel traffic in 

portions of the Atlantic Ocean adjacent 

to Ocean City, New Jersey during the 

aerial demonstration. 

DATES: Comments and related material 

must be received by the Coast Guard on 

or before September 21, 2009 Requests 

for public meetings must be received by 

the Coast Guard on or before August 28, 

2009. 

ADDRESSES: You may submit comments 

identified by docket number USCG– 

2009–0720 using any one of the 

following methods: 

(1) Federal eRulemaking Portal: 

http://www.regulations.gov. 

(2) Fax: 202–493–2251. 

(3) Mail: Docket Management Facility 

(M–30), U.S. Department of 

Transportation, West Building Ground 

Floor, Room W12–140, 1200 New Jersey 

Avenue, SE., Washington, DC 20590– 

0001. 

(4) Hand delivery: Same as mail 

address above, between 9 a.m. and 5 

p.m., Monday through Friday, except 

Federal holidays. The telephone number 

is 202–366–9329. 

To avoid duplication, please use only 

one of these four methods. See the 

‘‘Public Participation and Request for 

Comments’’ portion of the 

SUPPLEMENTARY INFORMATION section 

below for instructions on submitting 

comments. 

FOR FURTHER INFORMATION CONTACT: If 

you have questions on this proposed 

rule, call or e-mail Lieutenant Rebecca 

Walthour, Chief of Waterways 

Management Branch, Coast Guard 

Sector Delaware Bay, at 215–271–4889, 

e-mail Rebecca.A.Walthour@uscg.mil. If 

you have questions on viewing or 

submitting material to the docket, call 

Renee V. Wright, Program Manager, 

Docket Operations, telephone 202–366– 

9826. 

SUPPLEMENTARY INFORMATION: 

Public Participation and Request for 

Comments 

We encourage you to participate in 

this rulemaking by submitting 

comments and related materials. All 

comments received will be posted 

without change to http:// 

www.regulations.gov and will include 

any personal information you have 

provided. 

Submitting Comments 

If you submit a comment, please 

include the docket number for this 

rulemaking (USCG–2009–0720), 

indicate the specific section of this 

document to which each comment 

applies, and provide a reason for each 

suggestion or recommendation. You 

may submit your comments and 

material online (via http:// 

www.regulations.gov) or by fax, mail, or 

hand delivery, but please use only one 

of these means. If you submit a 

comment online via http:// 

www.regulations.gov, it will be 

considered received by the Coast Guard 

when you successfully transmit the 

comment. If you fax, hand deliver, or 

mail your comment, it will be 

considered as having been received by 

the Coast Guard when it is received at 

the Docket Management Facility. We 

recommend that you include your name 

and a mailing address, an e-mail 

address, or a telephone number in the 

body of your document so that we can 

contact you if we have questions 

regarding your submission. 

To submit your comment online, go to 

http://www.regulations.gov, click on the 

‘‘submit a comment’’ box, which will 

then become highlighted in blue. In the 

‘‘Document Type’’ drop down menu, 

select ‘‘Notices’’ and insert ‘‘USCG– 

2009–0720’’ in the ’’Keyword’’ box. 

Click ‘‘Search’’ then click on the balloon 

shape in the Actions column. If you 

submit your comments by mail or hand 

delivery, submit them in an unbound 

format, no larger than 81⁄2; by 11 inches, 

suitable for copying and electronic 

filing. If you submit comments by mail 

and would like to know that they 

reached the Facility, please enclose a 

stamped, self-addressed postcard or 

envelope. We will consider all 

comments and material received during 

the comment period and may change 

the rule based on your comments. 

Viewing Comments and Documents 

To view comments, as well as 

documents mentioned in this preamble 

as being available in the docket, go to 

http://www.regulations.gov, click on the 

‘‘read comments’’ box, which will then 

become highlighted in blue. In the 

‘‘Keyword’’ box, insert USCG–2009– 

0720 and click ‘‘Search.’’ Click the 

‘‘Open Docket Folder’’ in the ‘‘Actions’’ 

column. You may also visit the Docket 

Management Facility in Room W12–140 

on the ground floor of the Department 

of Transportation West Building, 1200 

New Jersey Avenue, SE., Washington, 

DC 20590, between 9 a.m. and 5 p.m., 

Monday through Friday, except Federal 

holidays. We have an agreement with 


CPrice-Sewell on DSKGBLS3C1PROD with PROPOSALS